Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Study:

Evaluation of Docetaxel in Recurrent, Platinum Resistant, Refractory and Paclitaxel Refractory Ovarian Cancer and Primary Peritoneal Carcinoma

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or refractory ovarian or primary peritoneal cancer.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Drug: docetaxel Phase 2

Verified by Gynecologic Oncology Group May, 2003

Sponsored by: Gynecologic Oncology Group
Information provided by: Gynecologic Oncology Group
ClinicalTrials.gov identifier: NCT00004037

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

Peter G. Rose, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site